Background:Acinetobacter baumannii has evolved from an opportunistic pathogen into a common and persistent nosocomial bacterium capable of causing severe infections during endemic and epidemic periods. Methods: The study period extended from January 1999 to December 2011 and involved patients hospitalized at the Hospital Civil de Guadalajara, Fray Antonio Alcalde, Jalisco, Mexico. From each patient, a single isolate was obtained, and a total of 3,680 unique isolates were collected. Susceptibility tests were performed according to the guidelines of the Clinical and Laboratory Standards Institute. Results:A. baumannii has disseminated throughout the Hospital Civil de Guadalajara, Fray Antonio Alcalde, since 1999. A. baumannii isolates obtained from patients treated in the adult intensive care unit represent the majority of the isolates that have been collected. In addition, A. baumannii was isolated from the adult neurosurgical ward and the adult internal medicine ward, and these isolates were frequently obtained from secretions. A persistent decrease in the susceptibility of A. baumannii isolates to meropenem (92% in 1999 to 12% in 2011), imipenem and amikacin has been observed. Conclusions:A. baumannii became an endemic nosocomial pathogen during the study period at the Hospital Civil de Guadalajara, Fray Antonio Alcalde, and has exhibited a persistent decrease in susceptibility to all categories of antimicrobial agents over the past 13 years.

Journal Section:
Editor's choice
Keywords:
Resistance patterns, <italic>Acinetobacter baumannii</italic>, Antimicrobial susceptibility
1.
Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA: Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007;51:3471-3484.
https://doi.org/10.1128%2FAAC.01464-06
[PubMed]
2.
Peleg AY, Seifert H, Paterson DL: Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008;21:538-582.
[PubMed]
https://doi.org/10.1128%2FCMR.00058-07
3.
Munoz-Price LS, Weinstein RA: Acinetobacter infection. N Engl J Med 2008;358:1271-1281.
[PubMed]
https://doi.org/10.1056%2FNEJMra070741
4.
de Benedictis FM, Osimani P, Gabriele C: Acinetobacter baumannii infections in children. Lancet Infect Dis 2010;10:143-144.
[PubMed]
https://doi.org/10.1016%2FS1473-3099%2810%2970030-X
5.
Sengstock DM, Thyagarajan R, Apalara J, Mira A, Chopra T, Kaye KS: Multidrug-resistant Acinetobacter baumannii: an emerging pathogen among older adults in community hospitals and nursing homes. Clin Infect Dis 2010;50:1611-1616.
[PubMed]
https://doi.org/10.1086%2F652759
6.
Shelburne SA 3rd, Singh KV, White AC Jr, Byrne L, Carmer A, Austin C, Graviss E, Stager C, Murray BE, Atmar RL: Sequential outbreaks of infections by distinct Acinetobacter baumannii strains in a public teaching hospital in Houston, Texas. J Clin Microbiol 2008;46:198-205.
[PubMed]
https://doi.org/10.1128%2FJCM.01459-07
7.
Runnegar N, Sidjabat H, Goh HM, Nimmo GR, Schembri MA, Paterson DL: Molecular epidemiology of multidrug-resistant Acinetobacter baumannii in a single institution over a 10-year period. J Clin Microbiol 2010;48:4051-4056.
[PubMed]
https://doi.org/10.1128%2FJCM.01208-10
8.
van den Broek PJ, van der Reijden TJ, van Strijen E, Helmig-Schurter AV, Bernards AT, Dijkshoorn L: Endemic and epidemic Acinetobacter species in a university hospital: an 8-year survey. J Clin Microbiol 2009;47:3593-3599.
[PubMed]
https://doi.org/10.1128%2FJCM.00967-09
9.
Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM: CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128-140.
[PubMed]
https://doi.org/10.1016%2F0196-6553%2888%2990053-3
10.
Hamouda A, Evans BA, Towner KJ, Amyes SG: Characterization of epidemiologically unrelated Acinetobacter baumannii isolates from four continents by use of multilocus sequence typing, pulsed-field gel electrophoresis, and sequence-based typing of bla(OXA-51-like) genes. J Clin Microbiol 2010;48:2476-2483.
[PubMed]
https://doi.org/10.1128%2FJCM.02431-09
11.
Seifert H, Dolzani L, Bressan R, van der Reijden T, van Strijen B, Stefanik D, Heersma H, Dijkshoorn L: Standardization and interlaboratory reproducibility assessment of pulsed-field gel electrophoresis-generated fingerprints of Acinetobacter baumannii. J Clin Microbiol 2005;43:4328-4335.
[PubMed]
https://doi.org/10.1128%2FJCM.43.9.4328-4335.2005
12.
Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B: Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995;33:2233-2239.
[PubMed]
13.
Walsh TR, Bolmstrom A, Qwarnstrom A, Gales A: Evaluation of a new Etest for detecting metallo-beta-lactamases in routine clinical testing. J Clin Microbiol 2002;40:2755-2759.
[PubMed]
https://doi.org/10.1128%2FJCM.40.8.2755-2759.2002
14.
Yong D, Lee K, Yum JH, Shin HB, Rossolini GM, Chong Y: Imipenem-EDTA disk method for differentiation of metallo-beta-lactamase-producing clinical isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol 2002;40:3798-3801.
[PubMed]
https://doi.org/10.1128%2FJCM.40.10.3798-3801.2002
15.
Weisenberg SA, Schuetz AN, Alexander EA, Eiss B, Behta M, Saiman L, Larone DH, Jenkins SG, Rhee KY: Endemic Acinetobacter baumannii in a New York hospital. PLoS One 2011;6:e28566.
[PubMed]
https://doi.org/10.1371%2Fjournal.pone.0028566
16.
Manikal VM, Landman D, Saurina G, Oydna E, Lal H, Quale J: Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis 2000;31:101-106.
[PubMed]
https://doi.org/10.1086%2F313902
17.
D'Agata EM, Thayer V, Schaffner W: An outbreak of Acinetobacter baumannii: the importance of cross-transmission. Infect Control Hosp Epidemiol 2000;21:588-591.
[PubMed]
https://doi.org/10.1086%2F501808
18.
Ledizet M, Murray TS, Puttagunta S, Slade MD, Quagliarello VJ, Kazmierczak BI: The ability of virulence factor expression by Pseudomonas aeruginosa to predict clinical disease in hospitalized patients. PLoS One 2012;7:e49578.
[PubMed]
https://doi.org/10.1371%2Fjournal.pone.0049578
19.
Tilley PA, Roberts FJ: Bacteremia with Acinetobacter species: risk factors and prognosis in different clinical settings. Clin Infect Dis1994;18:896-900.
[PubMed]
https://doi.org/10.1093%2Fclinids%2F18.6.896
20.
Maslow JN, Glaze T, Adams P, Lataillade M: Concurrent outbreak of multidrug-resistant and susceptible subclones of Acinetobacter baumannii affecting different wards of a single hospital. Infect Control Hospital Epidemiol 2005;26:69-75.
[PubMed]
https://doi.org/10.1086%2F502489
21.
Lee SO, Kim NJ, Choi SH, Hyong Kim T, Chung JW, Woo JH, Ryu J, Kim YS: Risk factors for acquisition of imipenem-resistant Acinetobacter baumannii: a case-control study. Antimicrob Agents Chemother 2004;48:224-228.
[PubMed]
https://doi.org/10.1128%2FAAC.48.1.224-228.2004
22.
Garza-Gonzalez E, Llaca-Diaz JM, Bosques-Padilla FJ, Gonzalez GM: Prevalence of multidrug-resistant bacteria at a tertiary-care teaching hospital in Mexico: special focus on Acinetobacter baumannii. Chemotherapy 2010;56:275-279.
[PubMed]
https://doi.org/10.1159%2F000319903
23.
Fukuta Y, Clarke LG, Shields RK, Wagener MM, Pasculle AW, Doi Y: Lack of seasonality in the occurrence of multidrug-resistant Acinectobacter baumannii complex. Infect Control Hosp Epidemiol 2012;33:1051-1052.
[PubMed]
https://doi.org/10.1086%2F667741
24.
Fournier PE, Richet H: The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006;42:692-699.
[PubMed]
https://doi.org/10.1086%2F500202
25.
Apisarnthanarak A, Warren DK, Fraser VJ: Creating a cohort area to limit transmission of pandrug-resistant Acinetobacter baumannii in a Thai tertiary care center. Clin Infect Dis 2009;48:1487-1488.
[PubMed]
https://doi.org/10.1086%2F598512
26.
Gonzalez-Chavez MI, Morfin-Otero R, Jarillo-Quijada C, Gayosso-Vazquez E, Rodriguez-Noriega E, Santos-Preciado JI, Giono-Cerezo S, Alpuche-Aranda CM, Alcantar-Curiel MD: First report of blavim-4, blaimp-1 and blaoxa-24-producing Acinetobacter baumannii clones isolated from nosocomial infections in Mexico (abstract C2-648). Abstracts of the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Ill., September 2011.
27.
Gales AC, Castanheira M, Jones RN, Sader HS: Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010). Diagn Microbiol Infect Dis 2012;73:354-360.
[PubMed]
https://doi.org/10.1016%2Fj.diagmicrobio.2012.04.007
28.
Esterly JS, Griffith M, Qi C, Malczynski M, Postelnick MJ, Scheetz MH: Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections. Antimicrob Agents Chemother 2011;55:4844-4849.
[PubMed]
https://doi.org/10.1128%2FAAC.01728-10
29.
Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, Barrero-Almodovar AE, Garcia-Garmendia JL, Bernabeu-Wittel IM, Gallego-Lara SL, Madrazo-Osuna J: Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003;36:1111-1118.
[PubMed]
https://doi.org/10.1086%2F374337
30.
Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E: Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 2008;46:567-570.
[PubMed]
https://doi.org/10.1086%2F526775
31.
Fishbain J, Peleg AY: Treatment of Acinetobacter infections. Clin Infect Dis 2010;51:79-84.
[PubMed]
https://doi.org/10.1086%2F653120
© 2013 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2013
You do not currently have access to this content.